Taisho Pharmaceutical Co., Ltd.

Toyama Chemical Co., Ltd.

Fujifilm Toyama Chemical Co., Ltd.

Tetsuya Yabuuchi

Naoya Ono

Fumiyasu Shiozawa

Tetsuo Takayama

Hironori Katakai

Yusuke Oka

Masakazu Sato

Fumito Uneuchi

Takeshi Koami

Masato Takahashi

Yoshinori Sekiguchi

Hajime Asanuma

Tomomi Ota

Makoto Yagi

Takahiro Oi

Hiroki Urabe

Hajime Takashima

Hironori Kotsubo

Shoichi Kuroda

Muneo Shoji

Yasuko Kawaguchi

Risa Tsuruta

Yoichiro Suga

Rie Nishikawa

Hideaki Amada

Madoka Kawamura

Daisuke Wakasugi

Yuko Matsunaga

Hiroki Umemiya

Akiko Ikeda

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria includingand its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. 

Hydroxamic acid derivative

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria includingand its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof: 

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase &#x3b3; inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

Aminothiazole derivative

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Isoquinoline derivative

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: (wherein Yrepresents a nitrogen atom or a group represented by CR, Yrepresents a nitrogen atom or a group represented by CR, Yrepresents a nitrogen atom or a group represented by CR, R, Rand R, which may be the same or different, each represent a hydrogen atom, etc. (excluding the case where Yis CR, Yis CRand Yis CR), X represents an oxygen atom, etc., Rrepresents a C-Calkyl group, etc., Rrepresents a C-Calkyl group, etc., Rrepresents an optionally substituted phenyl group, etc., Rrepresents a hydrogen atom, etc., and Rrepresents an optionally substituted phenyl group, etc.) has an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P), and is useful as a therapeutic agent for autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis, or age-related macular degeneration, etc.

[object Object]

An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P), and is useful as a pharmaceutical compound. A compound or a pharmaceutically acceptable salt thereof, which compound is represented by the formula below (where A represents an oxygen atom, a sulfur atom, a group represented by Formula &#x2014;SO&#x2014;, a group represented by Formula &#x2014;SO&#x2014;, or the like, Rrepresents a hydrogen atom, an alkyl group having 1-6 carbon atoms, or the like, Rrepresents a hydrogen atom or the like, Rrepresents an alkyl group having 1-6 carbon atoms, a cycloalkyl group having 3-6 carbon atoms, or the like, Rrepresents an aryl group, Rrepresents a hydrogen atom or an alkyl group having 1-6 carbon atoms and optionally substituted with a carboxyl group, and Rrepresents an alkyl group having 1-10 carbon atoms, a cycloalkyl group having 3-8 carbon atoms, an aryl group which is optionally substituted, or the like).

Triazole derivative

A compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof has an effect of inhibiting binding between S1P and its receptor Edg-1(S1P), and is useful as a pharmaceutical product. 

The present invention aims to provide compounds which have an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P) and which are useful for pharmaceutical purposes. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: [wherein Ar represents a monocyclic heterocyclic ring containing one or two nitrogen atoms, A represents an oxygen atom or the like, Y, Yand Yeach represent a carbon atom or a nitrogen atom, Rrepresents a hydrogen atom, a C-Calkyl group or the like, Rrepresents a C-Calkyl group, a C-Ccycloalkyl group or the like, Rrepresents a C-Calkyl group or the like, Rrepresents a hydrogen atom or a C-Calkyl group, and Rrepresents a C-Calkyl group or the like].

Binding inhibitor of sphingosine-1-phosphate

A thiazolylimidazole derivative represented by the formula or a pharmaceutically acceptable salt thereof, and an ALK5 inhibitor, an therapeutic agent for alopecia or a hair growth agent having the above as an active ingredient,wherein:  The present invention provides an inhibitory substance against ALK5 which is a TGF-&#x3b2; type I receptor and provides a hair growth stimulant or a hair growth agent based on its novel activities.

Thiazole derivative

Growing community of inventors

Toshima-ku, Japan

Tetsuya Yabuuchi